IGF-1 LR3: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 8 sources cited
Overview
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These modifications reduce binding to IGF-binding proteins (IGFBPs), which made the analogue about 2.5 to 3 times more potent than IGF-1 in rat studies. No human study of IGF-1 LR3 has been published.
Mechanism of Action
IGF-1 LR3 binds directly to the IGF-1 receptor (IGF-1R) on target cells, bypassing the normal regulatory system of IGF-binding proteins that sequester and limit endogenous IGF-1 activity. Upon binding, it activates the PI3K/Akt/mTOR signaling cascade — the central anabolic pathway controlling protein synthesis, cell proliferation, and apoptosis inhibition. This leads to muscle hypertrophy through increased satellite cell activation and myoblast fusion, enhanced amino acid uptake, and accelerated protein synthesis. Unlike GH secretagogues that work upstream, IGF-1 LR3 acts directly at the tissue level, producing potent local and systemic growth effects. It also promotes glucose uptake independently of insulin (via GLUT4 translocation) and in rats, local IGF-1 infusion raised muscle DNA content along with muscle protein, which points to satellite cells adding myonuclei rather than to new muscle fibres.
IGF-1 LR3 Benefits: What the Research Shows
- In rats, LR3 IGF-1 was about 2.5 to 3 times more potent than native IGF-1 because it binds IGF-binding proteins poorly, even though it binds the type 1 IGF receptor about 3 times less well (Biochemical Journal, 1992 and 1993)
- Animal studies showed local IGF-1 infusion made the infused rat muscle about 9% heavier, with more muscle protein and DNA (Journal of Applied Physiology, 1998)
- IGF-1 drives satellite cell proliferation, and local infusion in rats increased muscle DNA content, meaning added myonuclei; an increase in muscle fibre number has not been shown
- Research in severely burned children found that IGF-1 given with its binding protein IGFBP-3 improved net protein balance and muscle protein synthesis, most clearly in those who were catabolic
- Preclinical cancer research has investigated both pro- and anti-tumor effects of IGF-1 signaling — context-dependent outcomes
IGF-1 LR3 Dosage
- Systemic protocol: 20–60 mcg subcutaneous injection daily, split into 1–2 doses
- Post-workout protocol: 40–80 mcg subcutaneous injection immediately after training
- Site-specific (intramuscular): 20–40 mcg injected bilaterally into target muscle groups post-workout
- Cycle length: 4–6 weeks on, 4–6 weeks off (to prevent receptor desensitization and preserve insulin sensitivity)
- Start at 20 mcg/day and titrate up based on response and blood glucose monitoring
- Monitor blood glucose — IGF-1 LR3 can cause hypoglycemia, especially with concurrent insulin use
- Avoid combining with exogenous insulin without medical supervision
- Take with a carbohydrate-containing meal post-injection to mitigate hypoglycemia risk
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
IGF-1 LR3 Side Effects & Safety
Known Side Effects
- Hypoglycemia: the most significant acute risk — can be severe, especially in fasted states or combined with insulin
- Joint and muscle pain as tissues grow rapidly
- Jaw and extremity growth with chronic high-dose use (acromegaly-like effects)
- Organ growth with prolonged use at high doses. In rats, IGF-1 and its variants increased gut weight by up to 45%
- Water retention and edema
- Increased tumor growth risk — IGF-1R signaling promotes proliferation of both normal and malignant cells
- Headache and facial puffiness
Safety Profile
IGF-1 LR3 is a powerful growth factor with significant safety considerations. Unlike GH secretagogues, it directly activates growth pathways without physiological feedback regulation, creating genuine risks with misuse. Hypoglycemia is the most immediate danger and can be life-threatening — always have glucose available. Chronic use at high doses can produce acromegaloid features (enlarged jaw, hands, feet) and organ hypertrophy. The most serious long-term concern is cancer risk: a meta-analysis of case-control studies linked higher circulating IGF-1 with prostate cancer and premenopausal breast cancer, with associations that were modest and varied by site. Whether short-term use at moderate doses changes that risk is unknown, and the approved IGF-1 product is contraindicated in anyone with a malignancy or a history of one. Contraindicated in active malignancy, diabetes (without careful medical oversight), pregnancy, and individuals under 25 (growth plate concerns). Strict cycling is essential.
What to Expect
Week 1: Increased muscle fullness and pumps during training. Possible mild hypoglycemia symptoms (shakiness, sweating) — managed with carbohydrate intake. Enhanced recovery. Week 2–3: Noticeable increases in muscle size and vascularity. Strength gains begin. Appetite may increase. Some joint discomfort possible as growth outpaces connective tissue adaptation. Weeks 4–6: Users report gains of a few pounds of lean mass. No published human study of IGF-1 LR3 has measured body composition, so this rests on user reports. Recovery between sessions is dramatically improved. Body composition shifts visibly. After cycling off, gains are well-retained if training and nutrition remain consistent, unlike water-retention-based gains from other compounds.
Common Stacks
PEG-MGF
PEG-MGF activates muscle satellite cells while IGF-1 LR3 drives their proliferation and differentiation — sequential anabolic signaling
Ipamorelin
Ipamorelin stimulates endogenous GH which provides systemic context for IGF-1 LR3's direct tissue anabolic effects
BPC-157
BPC-157 supports tissue repair and tendon healing to keep connective tissue healthy during rapid muscle growth
Storage & Handling
Store lyophilized IGF-1 LR3 at -20°C for maximum stability (up to 24 months). Extremely sensitive to temperature once reconstituted — keep at 2–8°C and use within 2–3 weeks. Reconstitute with bacteriostatic water or 0.6% acetic acid solution for maximum stability. Do not shake. Aliquoting into single-use portions and freezing can extend usable life. Discard if solution becomes cloudy.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Tomas FM, Knowles SE, Owens PC, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J. 1992.
- Tomas FM, Knowles SE, Owens PC, et al. Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects. Biochem J. 1993.
- Adams GR, McCue SA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol (1985). 1998.
- Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026.
- Herndon DN, Ramzy PI, DebRoy MA, et al. Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann Surg. 1999.
- Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004.
- INCRELEX (mecasermin) injection: full prescribing information. Ipsen Biopharmaceuticals, Inc., via DailyMed. 2025.
- The Prohibited List 2026, section S2.3 Growth factors and growth factor modulators. World Anti-Doping Agency. 2026.
Related Peptides
Track IGF-1 LR3 in Your Protocol
Log your IGF-1 LR3 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free